Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06568562 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Study acronym: PRO-XL
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 79 wordsv7 See this version in full on ClinicalTrials.gov ↗
  2. 2 versions Re-verified since Oct 30, 2025, no change to tracked fieldsv5-v6
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2024 to Dec 9, 2024 · Site details revisedv4 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2024 to Dec 9, 2024
    • Site details revised
  4. Eligibility criteria revised Secondary endpoints: 10 to 7v3 Show 1 more changeShow less
    • Secondary endpoints: 10 to 7

    See this version in full on ClinicalTrials.gov ↗

  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a day. Participants will return to clinic for regular visits for checkups and tests.
Trial Details
NCT Number NCT06568562
Lead Sponsor University of Utah
Collaborators: Exelixis
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov